What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2024-03-27 compared with 2023-03-30 · 47 added, 20 removed, 4 unchanged (94% of the section changed)

1 unchanged sentence

Information and Current Stockholders

January 10, 2023, our common stock has been trading on the Nasdaq Capital Market LLC (“Nasdaq”) under the symbol “ATLX.”

Quotations for our common stock are available on nasdaq.com.

Prior to January 10, 2023, our common was quoted on the OTCQB

Marketplace (“OTCQB”) operated by the OTC Markets Group, Inc.

under the symbol “ATLXD.” The following

table sets forth, for each of the quarterly periods indicated, the range of high and low sales prices, in U.S.

dollars, for our common

stock for each quarter in 2021 and 2022.

(01/01-03/31)

(04/01-06/30)

(07/01-09/30)

(10/01-12/31)

(01/01-03/31)

(04/01-06/30)

(07/01-09/30)

(10/01-12/31)

of March 27, 2023, there were 239 holders of record of the Company’s common stock.

January 10, 2023, our common stock has been trading on the Nasdaq Capital Market LLC (“Nasdaq”) under the symbol “ATLX.” Prior to January 10, 2023, our common was quoted on the OTCQB Marketplace

(“OTCQB”) operated by the OTC Markets Group, Inc.

under the symbol “ATLXD.”

As of March 20, 2024, there were 132

holders of record of our common stock, which does not include beneficial owners for whom CEDE & Co.

or others act as nominees.

have not paid any cash dividends since our inception and do not expect to declare any cash dividends in the foreseeable future.

Sales of Unregistered Securities

Except as previously disclosed

in Item 15 of our Registration Statement on Form S-1 declared effective by the SEC on January 9, 2023, there have been no other sales

of unregistered securities during the period covered by this Annual Report.

addition to the sales of unregistered securities previously disclosed in our Quarterly Reports on Form 10-Q or Current Reports on Form

8-K (the “2023 Periodic Reports”), we consummated the following sales of unregistered securities during the fourth

quarter of fiscal 2023, which sales were exempt from registration under the Securities Act upon reliance on Section 4(a)(2) thereof,

and Regulation S promulgated thereunder:

November 20, 2023, we issued an aggregate of 18,001 shares of common stock upon exercise of three outstanding warrants that

were originally issued in July, August and November of 2021.

The warrants had exercise prices ranging from $9.00 to $15.00 per share

and we received proceeds of $222,015 in connection with such exercises.

November 20, 2023, we issued an aggregate of 40,000 shares of common stock upon exercise of a stock option held by a consultant

to us that was issued in exchange for services rendered.

The exercise price of the stock option was $7.00 per share, and

we received proceeds of $280,000 upon exercise.

December 11, 2023, we issued an aggregated of 18,003 shares of common stock upon exercise of six outstanding warrants that

were originally issued in August and December of 2021.

The warrants had exercise prices ranging from $9.00 to $15.00 per share and

we received proceeds of $191,035.50 in connection with such exercises.

December 21, 2023, we issued to a director an aggregate of 151,141 shares of common stock upon exercise for $0.0075 per

share of a stock option that had been granted in April of 2019.

December 22, 2023, and December 27, 2023, we issued an aggregate of 30,630 shares of common stock upon exercise of six outstanding

warrants, four of which were originally issued in August, September, October and December 2021 and two of which were issued in August

and September of 2022.

The warrants had exercise prices ranging from $5.625 to $15.00 per share.

An aggregate of 3,962 of shares

of common stock were issued pursuant to cashless exercises of two of the warrants, for

which we received no proceeds.

As the result of the exercises of the remaining four warrants, we received cash proceeds of $305,016.

In May 2023 and December 2023, the Company issued to Mr.

Fogassa an aggregate of 180,819 shares of common stock for achievement of performance

targets in 2022, and upon exercise of a stock option granted in April 2019.

Finally, in April 2023,

addition to the sales of unregistered securities disclosure included in our 2023 Periodic Reports, and as otherwise disclosed above,

during the first three quarters of fiscal year ended December 2023, we issued an aggregate of 85,042 shares of common stock pursuant

to certain employee and consultant compensation arrangements prior to the adoption of

our 2023 Stock Incentive Plan;

240,796 shares of common stock pursuant to the cashless exercises of warrants and 16,667 shares of

common stock pursuant to a cash exercise of a warrant, for which we received $137,502 in cash proceeds, each originally issued in

and 28,149 shares of common stock in other transactions exempt from the registration requirements of the Securities

Act., for which we received cash proceeds of $380,012.

of Equity Securities by the Issuer and Affiliated Purchasers

we nor any affiliated purchaser or anyone acting on our behalf or on behalf of an affiliated purchaser made any purchases of shares of

our common stock during the year ended December 31, 2023.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity